Compare ADMA Biologics Inc (ADMA) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Fidelity National Information Servcs Inc — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Fidelity National Information Servcs Inc trades at $41.17 (market cap $22.02B). The key difference: Fidelity National Information Servcs Inc is far larger — about 10.3× ADMA Biologics Inc's market cap, and Fidelity National Information Servcs Inc pays a 3.94% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | FIS | |
|---|---|---|
Market Cap | $2.13B | $22.02B |
Sector | Health | Technology |
52-Week High | $20.38 | $81.94 |
52-Week Low | $7.60 | $37.72 |
Enterprise Value | $2.20B | $42.41B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
FIS trades at $42.6, up 1.91% today, with a bullish technical signal despite mixed moving averages. The company shows improving fundamentals with 2025 revenue of $10.68B and a net income margin of 23.35%, supported by a low P/E of 8. Recent news highlights strategic wins, including partnerships with Frankfurt International Bank and First Commerce Bank for cloud-native banking solutions, reinforcing its competitive positioning in financial technology.
The outlook is positive with a consensus price target of $55.40, implying significant upside. Key opportunities include continued revenue growth and margin expansion, but risks involve a high debt load and macroeconomic pressures on lending markets. Analyst sentiment is strongly bullish with 58% buy ratings, though investors should monitor execution on debt management and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
